Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
1(10%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_1
6
60%
Ph phase_2
4
40%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (60.0%)
Phase 24 (40.0%)

Trials by Status

completed880%
recruiting110%
withdrawn110%

Recent Activity

1 active trials
Showing 5 of 10
completedphase_2

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

NCT04669808
recruitingphase_2

STP705 Injection for Submental Fat Reduction

NCT07677683
withdrawnphase_1

Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars

NCT05196373
completedphase_2

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

NCT04844840
completedphase_1

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

NCT04676633
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04669808Phase 2

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

Completed
NCT07677683Phase 2

STP705 Injection for Submental Fat Reduction

Recruiting
NCT05196373Phase 1

Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars

Withdrawn
NCT04844840Phase 2

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

Completed
NCT04676633Phase 1

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Completed
NCT05422378Phase 1

A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty

Completed
NCT05421013Phase 1

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

Completed
NCT04844983Phase 2

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
NCT04293679Phase 1

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

Completed
NCT02956317Phase 1

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10